NIFTY23,916.451.06%
SENSEX76,718.831.22%
BANKNIFTY56,112.950.34%
NIFTY IT28,546.655.24%
PHARMA22,629.201.55%
AUTO25,670.850.61%
FMCG50,783.800.70%
METAL12,773.350.10%
REALTY778.501.29%
ENERGY39,914.000.21%
NIFTY23,916.451.06%
SENSEX76,718.831.22%
BANKNIFTY56,112.950.34%
NIFTY IT28,546.655.24%
PHARMA22,629.201.55%
AUTO25,670.850.61%
FMCG50,783.800.70%
METAL12,773.350.10%
REALTY778.501.29%
ENERGY39,914.000.21%

ICICI Securities Releases Q4 Earnings Estimates for Healthcare Sector

ICICI Securities has published its earnings estimates for the Healthcare sector, focusing on the fourth quarter of the fiscal year 2022-2023, spanning January to March 2026. According to the brokerage house, Thyrocare is expected to report a net profit of Rs. 40.1 crore, marking a significant year-over-year increase of 84.9%.

The estimated net sales for Thyrocare are projected to rise by 14.3 percent year-over-year, reaching Rs. 214 crore. On a quarterly basis, the net sales are expected to increase by 9.4 percent.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) are likely to experience a notable growth, with an estimated rise of 16.8 percent year-over-year, reaching Rs. 67.4 crore. On a quarterly basis, EBITDA is expected to increase by 16.6 percent.

Read also: Mindtree Shares Plummet 6% on Missed Q4 Earnings Estimates, Citigroup Lowers Price Target

MetricQ4 FY 2022-23 (Estimate)Q-o-Q GrowthY-o-Y Growth
Net Profit (Rs. crore)40.118.4%84.9%
Net Sales (Rs. crore)2149.4%14.3%
EBITDA (Rs. crore)67.416.6%16.8%

Investor Takeaway

Investors can expect a significant increase in Thyrocare's net profit in Q4.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@iposcanner.ai.

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.